Theralase Technologies Inc. (CVE:TLT – Get Free Report)’s share price fell 4.6% during trading on Friday . The company traded as low as C$0.30 and last traded at C$0.31. 300,320 shares traded hands during trading, an increase of 10% from the average session volume of 272,498 shares. The stock had previously closed at C$0.33.
Theralase Technologies Stock Down 4.6%
The company has a quick ratio of 3.40, a current ratio of 1.91 and a debt-to-equity ratio of 14.85. The firm has a 50 day simple moving average of C$0.20 and a 200-day simple moving average of C$0.20. The stock has a market cap of C$82.12 million, a P/E ratio of -17.22 and a beta of -0.13.
Theralase Technologies Company Profile
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Read More
- Five stocks we like better than Theralase Technologies
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- What a Former CIA Agent Knows About the Coming Collapse
- Wall Street’s New Sports Prediction Trade
- Trade this between 9:30 and 10:45 am EST
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
